← All trials
NCT03058666
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2017
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 658
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ONYLead sponsor
- Albany Medical CollegeStudy chair
- AHRMCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.